$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000117887920000023 Filed on May 07, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$60.53M	$34.05M
YoY Change	77.77%	103.92%
Cost Of Revenue	$6.552M	$4.055M
YoY Change	61.58%	55.07%
Gross Profit	$53.97M	$29.99M
YoY Change	79.96%	112.99%
Gross Profit Margin	89.17%	88.09%
Selling, General & Admin	$40.22M	$44.30M
YoY Change	-9.23%	61.71%
% of Gross Profit	74.51%	147.72%
Research & Development	$89.12M	$64.59M
YoY Change	37.97%	58.32%
% of Gross Profit	165.12%	215.37%
Depreciation & Amortization	$1.764M	$991.0K
YoY Change	78.0%	2.27%
% of Gross Profit	3.27%	3.3%
Operating Expenses	$132.0M	$111.3M
YoY Change	18.66%	58.36%
Operating Profit	-$78.06M	-$81.28M
YoY Change	-3.96%	44.67%
Interest Expense	$3.729M	$6.454M
YoY Change	-42.22%	43.81%
% of Operating Profit
Other Income/Expense, Net	-$8.316M	$1.086M
YoY Change	-865.75%	-60.71%
Pretax Income	-$88.59M	-$120.1M
YoY Change	-26.26%	134.14%
Income Tax	$361.0K	$168.0K
% Of Pretax Income
Net Earnings	-$88.95M	-$120.3M
YoY Change	-26.06%	141.0%
Net Earnings / Revenue	-146.96%	-353.34%
Basic Earnings Per Share
Diluted Earnings Per Share	-$346.1K	-$563.4K
COMMON SHARES
Basic Shares Outstanding	257.2M shares	223.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$338.9M	$438.3M
YoY Change	-22.68%	-22.08%
Cash & Equivalents	$123.2M	$96.35M
Short-Term Investments	$215.6M	$342.0M
Other Short-Term Assets	$15.70M	$13.60M
YoY Change	15.44%	28.3%
Inventory	$12.83M	$8.167M
Prepaid Expenses
Receivables	$40.56M	$22.96M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$407.9M	$483.0M
YoY Change	-15.55%	-18.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$47.69M	$13.29M
YoY Change	258.93%	49.28%
Goodwill	$197.8M	$197.8M
YoY Change	0.0%
Intangibles	$23.00M	$23.00M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$29.41M	$11.27M
YoY Change	161.11%	101.16%
Total Long-Term Assets	$330.4M	$281.7M
YoY Change	17.31%	1.32%
TOTAL ASSETS
Total Short-Term Assets	$407.9M	$483.0M
Total Long-Term Assets	$330.4M	$281.7M
Total Assets	$738.3M	$764.7M
YoY Change	-3.45%	-12.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.24M	$60.60M
YoY Change	-73.2%	38.67%
Accrued Expenses	$74.20M	$2.500M
YoY Change	2868.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$91.71M	$65.87M
YoY Change	39.24%	-53.18%
LONG-TERM LIABILITIES
Long-Term Debt	$149.7M	$168.8M
YoY Change	-11.32%	1.2%
Other Long-Term Liabilities	$4.214M	$3.609M
YoY Change	16.76%	-89.54%
Total Long-Term Liabilities	$4.214M	$3.609M
YoY Change	16.76%	-98.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$91.71M	$65.87M
Total Long-Term Liabilities	$4.214M	$3.609M
Total Liabilities	$335.8M	$313.0M
YoY Change	7.26%	-10.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.900B	-$1.533B
YoY Change	23.98%	-400236.03%
Common Stock	$2.241B	$1.973B
YoY Change	13.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$402.6M	$451.7M
YoY Change
Total Liabilities & Shareholders Equity	$738.3M	$764.7M
YoY Change	-3.45%	-12.1%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$88.95M	-$120.3M
YoY Change	-26.06%	141.0%
Depreciation, Depletion And Amortization	$1.764M	$991.0K
YoY Change	78.0%	2.27%
Cash From Operating Activities	-$107.9M	-$78.55M
YoY Change	37.43%	58.61%
INVESTING ACTIVITIES
Capital Expenditures	$806.0K	$2.944M
YoY Change	-72.62%	259.46%
Acquisitions
YoY Change
Other Investing Activities	$94.05M	$83.01M
YoY Change	13.3%	-145.67%
Cash From Investing Activities	$93.25M	$80.07M
YoY Change	16.46%	-143.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.487M	$17.38M
YoY Change	-108.55%	-94.14%
NET CHANGE
Cash From Operating Activities	-$107.9M	-$78.55M
Cash From Investing Activities	$93.25M	$80.07M
Cash From Financing Activities	-$1.487M	$17.38M
Net Change In Cash	-$20.45M	$16.55M
YoY Change	-223.53%	-74.66%
FREE CASH FLOW
Cash From Operating Activities	-$107.9M	-$78.55M
Capital Expenditures	$806.0K	$2.944M
Free Cash Flow	-$108.7M	-$81.49M
YoY Change	33.45%	61.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	fold	Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases	6260000	USD
CY2019Q4	fold	Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases	5342000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19260000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17604000	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	257449955	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	255417869	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	257449955	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	255417869	shares
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	1536000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-56000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-33497
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Amicus Therapeutics, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	71-0869350
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Cedar Brook Drive,
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury,
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
CY2020Q1	dei	City Area Code CityAreaCode	(609)
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	662-2000
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2020Q1	dei	Trading Symbol TradingSymbol	FOLD
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	257664403	shares
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20008000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123231000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2020Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	215642000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	309903000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40555000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33284000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	12831000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15690000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	407949000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	520073000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32501000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33315000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47688000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47705000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	197797000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29414000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28317000	USD
CY2020Q1	us-gaap	Assets Assets	738349000	USD
CY2019Q4	us-gaap	Assets Assets	850207000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	16239000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21722000	USD
CY2020Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	66722000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	98651000	USD
CY2020Q1	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	1250000	USD
CY2019Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	1250000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7503000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7189000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	91714000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	128812000	USD
CY2020Q1	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	8906000	USD
CY2019Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	8906000	USD
CY2020Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2167000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2131000	USD
CY2020Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	147569000	USD
CY2019Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	147374000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	23612000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22681000	USD
CY2020Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5051000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5051000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52522000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53531000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4214000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5296000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	335755000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	373782000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	2607000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2598000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2238346000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2227225000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	6981000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	2785000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-169000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	40000	USD
CY2020Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1857558000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1768610000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	402594000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	738349000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	850207000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	60525000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34046000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6552000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4055000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	53973000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	29991000	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	89120000	USD
CY2019Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	64593000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40215000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44303000	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-931000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1383000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1764000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	991000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	132030000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	111270000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-78057000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-81279000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1515000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2639000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	3729000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	6454000	USD
CY2020Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36123000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8316000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1086000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88587000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120131000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	361000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	168000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-88948000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-120299000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	256968248	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	213519287	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-88948000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-120299000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4196000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1804000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-209000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	584000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3987000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1220000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84961000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-121519000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6077000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-7543000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12596000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-209000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4196000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-88948000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	402594000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	342912000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3953000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-1940000	USD
CY2019Q1	fold	Stock Issued During Period Value Contingent Consideration StockIssuedDuringPeriodValueContingentConsideration	9316000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12744000	USD
CY2019Q1	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	812000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	190758000	USD
CY2019Q1	fold	Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations	14632000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	584000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1804000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-120299000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	451668000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-88948000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-120299000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	231000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1649000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1764000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	991000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12596000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12744000	USD
CY2020Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36123000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	931000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1383000	USD
CY2020Q1	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-10662000	USD
CY2019Q1	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-325000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4016000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8358000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1001000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	251000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-345000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3059000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-35251000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8858000	USD
CY2020Q1	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-5334000	USD
CY2019Q1	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-3507000	USD
CY2020Q1	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	0	USD
CY2019Q1	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-1500000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-107942000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78546000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	106140000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	135187000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12088000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52178000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	806000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2944000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	93246000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	80065000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	21000	USD
CY2019Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	75000	USD
CY2020Q1	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	7543000	USD
CY2019Q1	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	1938000	USD
CY2020Q1	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	0	USD
CY2019Q1	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	14632000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6077000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3953000	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	812000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1487000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17384000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4265000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2350000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20448000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16553000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146341000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125893000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98928000	USD
CY2020Q1	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	254000	USD
CY2019Q1	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	3693000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	4846000	USD
CY2020Q1	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	0	USD
CY2019Q1	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	9316000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	589000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1900000000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2020 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div>
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">®</sup>. The Company's accounts receivable at March 31, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	60525000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34046000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123200000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	215600000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123231000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	123231000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	338844000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	190000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	161000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	338873000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123231000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	123231000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	215613000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	190000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	161000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	215642000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	338844000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	190000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	161000	USD
CY2020Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	338873000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309665000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309903000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	99500000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	42600000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	9500000	USD
CY2020Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2019	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123231000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96349000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2662000	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2579000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125893000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98928000	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5322000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6544000	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2900000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3660000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4609000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3837000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	12831000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
CY2020Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2019Q1	fold	Debt Instrument Convertible Debt Exchange Agreement Aggregate Principal Amount DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount	219300000	USD
CY2019Q1	fold	Debt Instrument Convertible Debt Exchange Agreement Shares Authorized For Issuance DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance	39000000.0	shares
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q1	fold	Debt Instrument Convertible Debt Exchange Agreement Accrued And Unpaid Interest DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest	1000000.0	USD
CY2019Q1	fold	Gain Loss On Extinguishment Of Debt Additional Paid In Capital GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital	190400000	USD
CY2019Q1	fold	Gain Loss On Extinguishment Of Debt Fair Value Of Common Shares Issued GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued	400000	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36100000	USD
CY2019Q1	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	14600000	USD
CY2019Q1	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	14600000	USD
CY2020Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3585000	USD
CY2019Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4813000	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	206000	USD
CY2019Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1559000	USD
CY2020Q1	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	25000	USD
CY2019Q1	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	83000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12596000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12744000	USD
CY2020Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	218619000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	23612000	USD
CY2020Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	3055000	USD
CY2020Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	26667000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	314270000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	22681000	USD
CY2019Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4419000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27100000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22681000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19700000	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-931000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1383000	USD
CY2020Q1	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
CY2019Q1	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	-316000	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23612000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20767000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-88948000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	213519287	shares
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-120299000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	256968248	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29664000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31912000	shares

Files In Submission

Name	View Source	Status
0001178879-20-000023-index-headers.html	Edgar Link	pending
0001178879-20-000023-index.html	Edgar Link	pending
0001178879-20-000023.txt	Edgar Link	pending
0001178879-20-000023-xbrl.zip	Edgar Link	pending
exhibit101.htm	Edgar Link	pending
exhibit102.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-03312020xex311.htm	Edgar Link	pending
fold-03312020xex312.htm	Edgar Link	pending
fold-03312020xex321.htm	Edgar Link	pending
fold-20200331.htm	Edgar Link	pending
fold-20200331.xsd	Edgar Link	pending
fold-20200331_cal.xml	Edgar Link	unprocessable
fold-20200331_def.xml	Edgar Link	unprocessable
fold-20200331_htm.xml	Edgar Link	completed
fold-20200331_lab.xml	Edgar Link	unprocessable
fold-20200331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q1 Form 10-Q Financial Statement

#000117887920000023 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q1 Form 10-Q Financial Statement

#000117887920000023 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold